The company conducts finishing and sterilization of products of all kinds, especially plastics, by treatment with ionizing radiation and provides related services. It offers treatments with ionizing radiation and EO-gas for professionals in medical, pharmaceutical, veterinary, cosmetic and food-packaging industries. The head office is located in Bautzen; additionally the company has operated a site in Kleve since 2023 that performs sterilization of medical products with ethylene oxide. Ionisos GmbH has been part of the lonisos group headquartered in France since 2016 and recorded revenue of EUR 7,450,387.73 in fiscal year 2024.
Veredelung oder Sterilisation von Erzeugnissen aller Art, insbesondere von Kunststoffen, durch die Behandlung mit ionisierenden Strahlen sowie die Erbringung von damit verbundenen Dienstleistungen.
Converted using the official Destatis and Eurostat correspondence tables; ISIC Rev. 4 is the United Nations' international industry classification.
This summary was generated with the help of AI. See our Data Quality Notice. Report error?
Source: German Commercial Register (Handelsregister) Dresden Local Court, HRB 26736 (as of 1 November 2026)
| Name | Type | City |
|---|---|---|
| Mohamed El Bounaamani | Geschäftsführer(in) | Grézieu-la-Varenne |
| Stefan Vinzens | Geschäftsführer(in) | Coswig |
Source: German Commercial Register (Handelsregister) Dresden Local Court, HRB 26736 (as of 1 November 2026)
| Date | Event Type | Event |
|---|---|---|
| 14.11.2016 | Company Name Change | Ionisos GmbH |
| 14.11.2016 | Gesellschaftsvertrag amended | Gesellschaftsvertrag |
| 09.01.2012 | Business Address Change | Nikolaus-Otto-Str. 5, 02625 Bautzen |
| Date | Type | Change | Total Capital |
|---|---|---|---|
| 25.06.2008 | Share Capital Set | — | 100.000 € |
Source: German Commercial Register (Handelsregister) Dresden Local Court, HRB 26736 (as of 1 November 2026)
| Year | Revenue | Profit | Balance | Employees |
|---|---|---|---|---|
| 2024 | €7,450,388 | -€4,855,997 | €52,424,050 | — |
| 2023 | €5,725,607 | -€4,306,731 | €50,635,031 | — |
| 2022 | €5,358,046 | -€560,291 | €47,461,044 | — |
| 2021 | €6,688,849 | €885,565 | €32,206,807 | — |
| 2020 | ≤ €12M1 | €1,364,991 | €20,394,714 | — |
| 2019 | ≤ €12M1 | €922,933 | €14,257,650 | — |
| 2018 | ≤ €12M1 | €642,839 | €12,682,252 | — |
| 2017 | ≤ €12M1 | €798,603 | €12,079,627 | — |
| 2016 | ≤ €12M1 | €563,680 | €11,175,219 | — |
| 2015 | ≤ €12M1 | €497,812 | €10,543,168 | — |
1 Small companies are not required to publish a profit-and-loss statement (§ 326 (1) HGB). The figure shown is the statutory ceiling under § 267 HGB where the balance-sheet total makes it binding — a company may exceed at most one of the three size criteria.
Sign in to download data
Source: German Commercial Register (Handelsregister) Dresden Local Court, HRB 26736 (as of 1 November 2026)
IQVIA RDS GmbH
Frankfurt am Main · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
Capricorn Scientific GmbH
Ebsdorfergrund · Abfüllen und Verpacken
ProPharma Group GmbH
Berlin · Sonstige Forschung und Entwicklung im Bereich Natur-, Ingenieur-, Agrarwissenschaften und Medizin
| Cost type | Amount | Share |
|---|---|---|
| Personnel Costs | €3,139,830 | 38.3% |
| Depreciation | €3,168,221 | 38.6% |
| Interest & Similar | €1,889,194 | 23.0% |
